In HELIOS-B (n=654), baseline tafamidis use (40%) did not significantly modify vutrisiran’s effect on mortality plus ...

Kalshi, a prediction betting market app, announced new contracts in July 2026 for FDA approvals on various cancer and ...

REMS certification requirements, split hospital/community EMRs, and limited trained infusion staffing create friction points ...

Andrew Kuykendall, MD, lead investigator for the VERIFY trial supporting the approval, said rusfertide is used to treat erythrocytosis in polycythemia vera.

Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, ...

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press. In its article, Becker's ...